Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Colorectal CancerMetastatic Cancer
Interventions
DRUG

floxuridine

DRUG

irinotecan hydrochloride

Trial Locations (10)

10021

Memorial Sloan-Kettering Cancer Center, New York

55455

University of Minnesota Cancer Center, Minneapolis

72205

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock

73112

Integris Oncology Services, Oklahoma City

40503-9985

Central Baptist Hospital, Lexington

02114

Massachusetts General Hospital Cancer Center, Boston

14263-0001

Roswell Park Cancer Institute, Buffalo

27599-7213

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

27157-1082

Comprehensive Cancer Center at Wake Forest University, Winston-Salem

02908-4735

University Medical Group, Providence

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00063960 - Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer | Biotech Hunter | Biotech Hunter